Business Context and Reporting Period
Company: Alterity Therapeutics Limited
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: January 2020
Date Filed: January 17, 2020
Principal Executive Office: Level 3, 460 Bourke Street, Melbourne, VIC 3000, Australia
This filing serves to incorporate by reference an Appendix 3B and 708A notice into the company's Registration Statements on Form S-8 (File No. 333-228671) and Form F-3 (Files No. 333-220886 and 333-231417).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing referencing a regulatory notice rather than a financial report.
Material Changes
No material financial changes versus a prior comparable period are disclosed in this text. The filing focuses on regulatory compliance regarding registration statements.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, specific risks, contingencies, or unusual items. The primary content is the incorporation of a 708A notice (typically related to equity compensation plans) into existing registration statements.
Investor Verification Checklist
- Verify the specific content of the referenced Appendix 3B and 708A notice, as the text only cites its existence.
- Confirm the status of the Registration Statements on Form S-8 and Form F-3 to understand the scope of the equity plans involved.
- Review the company's most recent Form 20-F for actual financial performance data, as this Form 6-K contains no financial figures.